SOMATOSTATIN RECEPTOR IMAGING OF NEUROENDOCRINE TUMORS

WEDNESDAY, OCTOBER 16, 2013
7:00pm EDT | 6:00pm CDT | 5:00pm MDT | 4:00pm PDT

A certified, one-hour live webinar for nuclear medicine technologists who image patients presenting with known or suspected neuroendocrine tumors

REGISTER AT www.icpme.us/NETS

FACULTY

Richard J. Campeau, MD, FACNM
Ochsner Health System
Clinical Professor of Radiology (NM) and Internal Medicine (Cardiology)
Louisiana State University and Tulane University Health Sciences Center
New Orleans, LA

COURSE OVERVIEW

In the past few decades, the overall incidence of neuroendocrine tumors (NETs) has increased, partly because of improved detection rates.1 Nevertheless, patients typically experience long delays of usually 5-7 years before diagnosis of NETs. These tumors display an array of symptoms, and there is a lack of sensitive and specific methods for early detection.2 Approximately 20% of patients with NETs have metastatic disease at presentation, and in half of those patients the primary tumor is not located at initial imaging.1

Somatostatin receptor scintigraphy (SRS) may be informative in imaging patients with newly diagnosed or suspected neuroendocrine tumors. This activity will discuss the role of the somatostatin hormone and its impact on the body, the relationship between somatostatin receptors (SSTR) and neuroendocrine tumors, types of NETS, the role of somatostatin receptor scintigraphy in the imaging of NETS, case study review, and challenges and pitfalls of SRS.

OBJECTIVES

At the conclusion of this activity, participants should be better able to:

1. Describe the structure of somatostatin (SST) hormone and its impact on the body
2. Discuss the relationship between somatostatin receptors (SSTR) and neuroendocrine tumors (NETS)
3. Explain the relationship between SSTR and somatostatin receptor scintigraphy (SRS) in the imaging of NETS
4. Describe the challenges and pitfalls of SRS imaging

ACCREDITATION AND CREDIT

The SNM/ITS, through its Verification Of Involvement in Continuing Education (VOICE) program, has approved this activity for a maximum of 1.00 continuing education hours (CEHs) ARRT Category A continuing education credit.

FOR QUESTIONS regarding this program, please contact ICPME:
Email: information@icpmed.com
Phone: 607-257-5860 x10


FUNDING PROVIDED BY

Mallinckrodt Pharmaceuticals

WEBINAR

WHEN YOU HEAR HOOF BEATS SOMETIMES THINK ZEBRAS!